Conventional Synthetic DMARD is named as an intervention in 2 current clinical trials in our USA register. None are recruiting at the moment. The most common phase is Phase 3. The sponsor with the most trials is SetPoint Medical Corporation (1). The most-studied condition is Rheumatoid Arthritis.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
NCT04539964 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis
|
Phase 3 | Active, closed | SetPoint Medical Corporation | USA |
|
At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]
NCT07163221 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis (RA)
|
Not applicable | Active, closed | SecondWave Systems Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| SetPoint Medical Corporation | 1 |
| SecondWave Systems Inc. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA register name Conventional Synthetic DMARD as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
SetPoint Medical Corporation (1) and SecondWave Systems Inc (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Conventional Synthetic DMARD works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Conventional Synthetic DMARD works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Conventional Synthetic DMARD (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.